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Abstract 
Leigh syndrome is the most common pediatric presentation of mitochondrial disease. 
This neurodegenerative disorder is genetically heterogeneous, and to date pathogenic 
mutations in more than 75 genes have been identified, encoded by two genomes 
(mitochondrial and nuclear). More than a third of these disease genes have been 
characterized in the last 5 years alone, reflecting the significant advances made in 
understanding its etiological basis. We review the diverse biochemical and genetic 
etiology of Leigh syndrome and associated clinical, neuroradiological and metabolic 
features that can provide clues for diagnosis. We discuss the emergence of genotype-
phenotype correlations, insights gleaned into the molecular basis of disease and 
available therapeutic options.  
Introduction 
Disorders of mitochondrial energy generation are the most frequent group of inherited 
metabolic disorders, with an estimated incidence of at least 1 in 5000 live births.1 The 
most common clinical presentation of mitochondrial disease in children is a 
progressive neurodegenerative disorder known as Leigh syndrome (MIM 25600, LS). 
LS has an estimated prevalence of ~1 per 40,000 live births,2 however much higher 
incidences have been observed in specific populations owing to founder mutations.3,4 
 
Since the identification of the first pathogenic mutation in a LS patient in 1991,5 more 
than 75 disease genes have been identified, highlighting the remarkable heterogeneity 
underlying this disorder. Nearly 30 of these LS disease genes have been characterized 
in the last 5 years alone, reflecting how the introduction and greater utility of 
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massively parallel sequencing (MPS) technology has transformed our ability to 
identify the genetic basis of disease. Beyond the identification of novel disease genes, 
MPS has also facilitated the identification of patients with mutations in known disease 
genes, enabling the emergence of genotype-phenotype relationships for this rare 
disorder. Advances in characterizing the genetic basis of LS have consolidated our 
understanding of the molecular basis of disease, revealing a diverse biochemical 
etiology consistent with the annotation of LS as a disorder of energy generation.2  
Clinical and neuroradiological features  
LS is clinically heterogeneous, with significant variation between patients with 
respect to age of onset, age of death and symptomatology. Generally, onset occurs by 
2 years of age,6 with symptoms often presenting during infection or illness after an 
initial period of normal development. Patients develop neurological symptoms 
including developmental delay and regression, hypotonia, ataxia, dystonia, and 
ophthalmological abnormalities including nystagmus and optic atrophy.2,6-8 The 
presentation can also be multisystemic; cardiac, hepatic, gastrointestinal and renal 
tubular dysfunction have been observed.9-12 Progression is often episodic, and 
typically results in death by 3 years of age.2,7,8,13 Adult-onset LS has been infrequently 
reported.14  	
Neurological decline in LS patients is associated with the development of bilateral 
symmetrical lesions within the brain stem and basal ganglia structures, which 
characterize the disease.13,15,16 These lesions are observed as regions of focal 
hyperintensity on T2-weighted magnetic resonance imaging (MRI), and elevated 
lactate may be detected by MR spectroscopy. Additional neuroradiological 
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abnormalities such as white matter involvement and cerebral atrophy may also be 
observed.17 In 1996, we defined criteria for a stringent diagnosis of LS, requiring that 
characteristic neuropathology or neuroradiology must be accompanied by progressive 
neurodegeneration with (1) clinical evidence of brainstem and or basal ganglia 
dysfunction, (2) intellectual and motor developmental delay and (3) elevated serum or 
CSF lactate indicating abnormal energy metabolism.2 In 2015, it would seem prudent 
to amend criterion (3) to ‘abnormal energy metabolism indicated by a severe defect in 
OXPHOS or PDHc activity, a molecular diagnosis in a gene related to mitochondrial 
energy generation or elevated serum or CSF lactate’.  Where patients do not fulfill 
these stringent criteria, a diagnosis of Leigh-like syndrome can be considered, 
particularly in patients with atypical neuroradiology or normal lactate levels.2  
The development of our understanding of the etiological basis of Leigh syndrome 
Since Denis Leigh’s first description of LS in 1951,18 there have been several key 
research milestones that have contributed to our understanding of the etiological basis 
of LS (Fig 1). The similarity of the neuropathology to Wernicke’s encephalopathy, a 
condition of thiamine deficiency, and findings of elevated blood lactate and pyruvate 
suggested that a metabolic abnormality was the underlying disease etiology.19,20 
Before the first genetic mutation was identified in 1991,5 40 years of clinical and 
biochemical investigation provided evidence that deficiency of the pyruvate 
dehydrogenase complex (PDHc), and of NADH:ubiquinone  oxidoreductase (complex 
I) and cytochrome c oxidase (complex IV) within the oxidative phosphorylation 
(OXPHOS) pathway, could cause LS.21-23 Together with the finding of abnormal 
mitochondrial morphology in skeletal muscle tissue from patients, these abnormalities 
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suggested a common theme of defective mitochondrial energy metabolism.22 
Subsequently LS was re-annotated as a mitochondrial encephalopathy.  
 
It has since been established that multiple other enzymatic deficiencies can underlie 
LS, mostly linked directly to OXPHOS or broader pathways of energy generation. 
The OXPHOS pathway of electron transfer, proton transport, and ATP synthesis 
comprises five multi-protein complexes located in the mitochondrial inner membrane 
(Fig 2). Biochemical defects in each of the five OXPHOS complexes, and the electron 
carrier coenzyme Q10 (CoQ10), have been observed in LS patients. PDHc enables the 
generation of electron donors for OXPHOS; hence PDHc deficiency also represents a 
disorder of energy generation. Complex I deficiency is the most common biochemical 
cause of LS with nearly a third of all LS disease genes associated with complex I 
deficiency. Isolated complex IV deficiency and multiple OXPHOS defects are also 
frequently observed, whereas defects of complexes II, III, V or of CoQ10 are relatively 
rare.2,6,7 Measurement of OXPHOS and PDHc enzymes in a patient biopsy or cell line 
is often undertaken to provide evidence of a biochemical defect in these pathways to 
support a clinical diagnosis of LS.  
The heterogeneous genetic basis of Leigh syndrome  
To date, pathogenic mutations in more than 75 genes have been identified in affected 
patients (Table 1, and see SupplementaryTable for more detailed information). Most 
of these disease genes encode structural components of the OXPHOS complexes, or 
proteins required for their assembly, stability and activity. As is the case for other 
mitochondrial diseases, there are several possible modes of inheritance including 
maternal (for mutations in mitochondrial DNA, mtDNA) and autosomal recessive or 
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X-linked (for nuclear-encoded genes). Despite the remarkable number of established 
disease genes, many LS patients remain without a genetic diagnosis, indicating that 
there are still more disease genes to be identified. 
 
The aim of this article is not to provide an in-depth review of all known forms of 
Leigh and Leigh-like syndrome, but rather to discuss the most relevant biochemical 
and genetic etiologies, associated clinical and biochemical features relevant for 
diagnosis, and therapeutic options (where available, summarized in Table 2). We 
focus on the more common nuclear-encoded genetic causes, as well as describing 
types of Leigh and Leigh-like syndrome caused by mtDNA mutations.   
Complex I deficiency  
The most frequent clinical presentation of complex I deficiency is LS,24 and complex 
I deficiency is the leading biochemical basis of LS.2,6,7 Mutations in the NADH 
Dehydrogenase (Ubiquinone) Fe-Sulfur protein 4 (NDUFS4) subunit are the most 
frequent autosomal recessive cause of complex I-associated LS, with more than 20 
cases reported.24 Interestingly, almost all patients reported with NDUFS4 mutations 
had LS, in contrast to mutations in other nuclear-encoded complex I subunits, which 
may be associated with heterogeneous phenotypes. Patients with NDUFS4 mutations 
display a characteristic LS presentation, experiencing onset and demise typically 
within the first 8 months of life and no later than 30 months. Neuroradiological 
features in these infants included bilateral symmetrical basal ganglia lesions in almost 
all cases, often extending down to the cerebral peduncles, pons and medulla, and 
frequently with associated cerebral atrophy.24,25 Approximately a third of all reported 
cases also had hypertrophic cardiomyopathy.  
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Mutations in NADH Dehydrogenase (Ubiquinone) Flavoprotein 1 (NDUFV1) and 
NDUFS1 have also been widely reported to cause LS. NDUFS1 mutations appear to 
be associated with an early age of death, with all reported patients presenting by 8.5 
months and succumbing by 4 years.24 Most patients with NDUFV1 mutations also 
died in early childhood, although a few cases were alive in late childhood.26,27 Thus, 
NDUFS4-, NDUFV1- and NDUFS1-mediated LS appear to be particularly severe 
forms of the disease. While all reported NDUFS4 mutations except one predict 
complete loss-of-function alleles, no patients have been described with two null 
alleles of NDUFV1 or NDUFS1, suggesting that complete loss of these two proteins 
may be incompatible with life.  
Complex II, Complex III and Coenzyme Q10 deficiencies 
Deficiencies of complex II, complex III or CoQ10 (ubiquinone) are rare causes of LS, 
and collectively underlie fewer than 10% of all cases.2,6,28 Mutations in the complex II 
subunit SDHA were the first nuclear mutations identified to cause OXPHOS 
disease.29 Some patients with SDHA mutations have a severe infantile presentation of 
LS with rapid demise,29 but other patients may experience a mild LS course, with 
survival into late childhood years, preservation of cognitive abilities and an ‘almost 
normal school life’.28,30 Nearly all patients with mutations in the complex III assembly 
factor TTC19 develop neuroimaging abnormalities consistent with LS.31 Occasional 
patients with LS and CoQ10 deficiency have been reported.9,32 Prompt recognition of 
this subgroup of LS is imperative, since these patients may respond to CoQ10 
supplementation and survive into adulthood,32 although this has not been consistently 
observed.33 One report described improvement of hepatic but not neurological 
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symptoms,34 and another patient with CoQ10 deficient LS due to PDSS2 mutations did 
not respond to treatment.9  
Complex IV deficiency 
Complex IV deficiency underlies ~15% of LS cases.2,6,7 Mutations in SURF1, 
encoding a complex IV assembly factor, are the most common cause of complex IV 
deficient LS and are one of the most frequently reported causes of LS, with more than 
200 cases described to date in the literature.35 Our recent natural history study of a 
SURF1 patient cohort highlighted the relatively homogenous clinical and biochemical 
presentation associated with SURF1 deficiency.35 However, a minority of patients 
with SURF1 mutations lack the neuroradiological hallmarks of LS or show atypical 
features such as leukodystrophy and atrophy.35,36 Survival analysis of 142 SURF1 
patients revealed a median age of death at 5.4 years,35 indicating longer survival in 
SURF1-associated LS than is observed for LS patients due to mutations in other 
complex IV disease genes SCO2, LRPPRC, and ETHE1.37-39 
 
LRPPRC mutations were originally reported in an isolated French-Canadian 
population.37,40 Characteristic clinical features associated with French-Canadian LS 
(LSFC, MIM 220111) include mild facial dysmorphism, liver pathology and a clinical 
course punctuated by episodes of acute metabolic decompensation that contribute 
significantly to mortality.3,37 Fifty-five of 56 reported cases inherited homozygous 
LRPPRC p.A354V mutations,37 reflecting a founder effect that has resulted in an 
incidence of LSFC of ~1 in 2000 live births (Table 3).3 Broader effects of LRPPRC 
dysfunction on mitochondrial post-transcriptional and translation processes have 
recently been recognized, including deficiency of ATP synthase.41 Despite presenting 
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as an isolated complex IV deficiency, the pathogenesis of LRPPRC mutations may 
therefore be attributable to a global defect of mitochondrial translation.  
 
Mutations in ETHE1 cause ethylmalonic encephalopathy (EE) (MIM 602473), a 
presentation that resembles LS clinically and neuroradiologically.38,42 The 
characterization of a role for ETHE1 in sulfide detoxification revealed EE as a 
manifestation of sulfide toxicity, whereby the associated isolated complex IV 
deficiency is a consequence of sulfide accumulation.43 Accordingly, therapeutic 
strategies that reduce sulfide accumulation resulted in clinical, biochemical and 
neuroradiological improvement in patients with ETHE1 mutations.44 
 
The only complex IV subunit with mutations causing LS is the recently reassigned 
subunit NDUFA4, which was previously thought to be a subunit of complex I. 
NDUFA4 mutations have been reported to cause childhood-onset LS with prominent 
epilepsy, learning difficulties and survival into adulthood.45 
Combined OXPHOS deficiencies 
Since mtDNA encodes structural components of complexes I, III, IV and V, a 
molecular defect that impairs mtDNA replication or translation can cause combined 
OXPHOS deficiency. Thus, mutations in various disease genes associated with 
mtDNA depletion or defective translation have been identified in patients with LS 
(see Table 1, see Supplementary Table, A for more detailed information). The 
predominant causes of LS associated with mtDNA depletion are mutations in 
SUCLA2 or SUCLG1, encoding subunits of succinyl-CoA synthetase which catalyzes 
the conversion of succinyl-CoA to succinate within the citric acid cycle. 
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Methylmalonic aciduria is frequently observed in these patients due to an 
accumulation of succinyl-CoA, and can be used to screen for these two defects in LS 
patients.46,47 Symptoms generally present in early infancy, and patients can survive 
into teenage years and young adulthood.48,49 Although patients with mutations in 
SUCLG1 and SUCLA2 manifest similarly, they can be differentiated by liver 
involvement (SUCLG1) or deafness (more common with SUCLA2 mutations).49 The 
SUCLA2 c.534+1G>A mutation has a high carrier frequency in the Faroe Islands 
owing to a founder effect, with an estimated LS incidence of 1 in 1700 in that 
population (Table 3).4 An interaction between succinyl-CoA synthetase and 
nucleoside diphosphate kinase, an enzyme involved in regulating mitochondrial 
nucleotide supply, has been hypothesized to account for mtDNA depletion in patients 
with SUCLA2 and SUCLG1 mutations.46  
 
Nuclear encoded mt-tRNA modifying enzymes are required for efficient 
mitochondrial translation, and mutations in these proteins represent a relatively new 
class of LS disease genes. Mitochondrial methionyl-tRNA formyltransferase 
(MTFMT) was the first LS disease gene of this type to be reported. MTFMT mutations 
were initially identified in two unrelated LS patients through targeted exome 
sequencing of the “MitoExome”,50 and subsequently identified in multiple other LS 
patients.51 Most cases carry at least one copy of the c.626C>T mutation, which has a 
carrier frequency of ~1 in 100 in the European population and so may account for a 
significant proportion of LS within this population.51 
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Mitochondrial DNA mutations causing Leigh syndrome associated with Complex 
I, Complex IV, Complex V and combined OXPHOS deficiencies 
Cohort studies have suggested that mtDNA mutations underlie approximately 10-20% 
of LS cases.2,6,7 To date, mutations in 13 of the 37 mtDNA-encoded genes have been 
described to cause LS, with the majority in genes encoding subunits of complexes I or 
V, or in mitochondrial tRNAs (see Table 1, and Supplementary Table, A for more 
detailed information). LS can also be caused by large-scale mtDNA deletions.2 The 
percentage of mtDNA molecules that carry the pathogenic mutation, known as the 
level of heteroplasmy, is an important determinant of the clinical presentation. As a 
severe manifestation of mitochondrial disease, LS is typically associated with high 
mutant loads of ≥ 90%, although MTND5 mutations associated with complex I 
deficiency are notable for their propensity to cause LS even when the mutant load is 
<50% in tissues including brain, where patients have been observed to survive into 
adulthood.52-54  
 
Mutations in complex I subunits MTND3 and MTND5, and in the complex V subunit 
MTATP6, are the most frequent mtDNA causes of LS. MTATP6 mutations represent 
the only established genetic basis of complex V-mediated LS, and mutations in this 
gene are estimated to underlie ~10% of all LS cases.2,6,7,55 The majority of these 
patients carry either the MTATP6 m.8993T>G or the less severe m.8993T>C 
mutation, which were among the first LS mutations described.56,57 Although 
uncommon, mutations in five mt-tRNAs have been identified in LS patients, 
including the well-known m.3243A>G MTTL1 mutation that is more commonly 
associated with the syndromes of mitochondrial encephalopathy with lactic acidosis 
and stroke-like episodes (MELAS) and maternally inherited diabetes and deafness 
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(MIDD), and the m.8344A>G in MTTK that typically causes myoclonic epilepsy with 
ragged red fibers (MERRF).58,59  
 
Although mtDNA is inherited maternally, many patients with mtDNA mutations lack 
any maternal family history suggesting mtDNA disease. This can be because the 
heteroplasmic mutant load in other family members is below the pathogenic threshold 
for that mutation. De novo mutations in mtDNA are also relatively common, so a 
mutation present at high levels of heteroplasmy in the proband can be undetectable in 
the mother and other maternal relatives.60,61 
Pyruvate dehydrogenase complex deficiency 
Evidence of elevated pyruvate and a lactate:pyruvate ratio of <20 can indicate PDHc 
deficiency in LS patients, with agenesis of the corpus callosum another common 
finding.62 Mutations in PDHA1, encoding the E1 alpha subunit, are the predominant 
cause of PDHc-associated LS.62,63 PDHA1 is an X-chromosome gene, but 
approximately equal numbers of boys and girls are diagnosed with PDHA1 
mutations.62 This pseudo-dominant inheritance is not surprising given that random X-
inactivation means that typically ~50% of cells will express the mutant allele. Skewed 
X-inactivation means that the biochemical diagnosis of PDHc deficiency in females 
can be challenging.64 Cohort studies of PDHc deficient individuals support previous 
observations that PDHA1 likely has a high de novo mutation rate.62,63  
 
Mutations in genes related to the PDHc co-factors lipoic acid and thiamine 
pyrophosphate (TPP) have more recently been described to cause LS. The LIPT1 and 
LIAS genes encode enzymes responsible for synthesis and transfer of the lipoic acid 
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cofactor, and the DLD gene encodes the PDHc subunit E3 dihydrolipoamide 
dehydrogenase. Patients with PDHc deficiency due to mutations in these genes 
present with a recognizable metabolic profile that reflects additional deficiency of ⍺-
ketoglutarate dehydrogenase and branched-chain ⍺-keto acid dehydrogenase.65-67 
PDHc deficiency due to mutations in genes associated with TPP availability (TPK1, 
SLC19A3 and SLC25A19) can be missed because of the presence of TPP in routine 
PDHc enzymatic assays, but may be identifiable when measuring PDHc activity in 
the absence of TPP.68,69 Mutations in the thiamine transporter SLC19A3 are well 
known to cause biotin/thiamine-responsive basal ganglia disease (BTBGD) (MIM 
607483), which phenocopies LS as a progressive encephalopathy with similar 
neuroimaging and episodic decline.70 Unlike typical LS, patients with BTBGD can 
show significant clinical and neuroradiological improvement following administration 
of thiamine and high dose biotin, particularly when commenced early in the disease 
course.71 Indeed patients with SLC19A3 mutations have been described with 
‘treatable’ or ‘reversible’ LS.71,72  
Disease genes associated with Leigh-like syndrome 
A diagnosis of Leigh-like syndrome usually refers to patients presenting with atypical 
neuropathology or neuroradiology, but can also reflect an atypical clinical 
presentation or course.2 Leigh-like presentations can display overlap with other 
mitochondrial encephalopathies, and many cases are caused by mutations in the same 
genes associated with LS. MTND5 and MTND3 mutations have been described to 
underlie a rare clinical presentation of a LS/MELAS overlap syndrome where patients 
simultaneously display neuroradiological and clinical characteristics of both 
syndromes,36,73 while large-scale mtDNA deletions can cause Pearson syndrome with 
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Leigh-like neuropathology.74,75 Furthermore, Leigh-like patients with POLG 
mutations generally lie on a spectrum between Alpers-Huttenlocher syndrome (MIM 
203700) and LS, where the neuropathology exhibits features characteristic of both 
syndromes and hepatic dysfunction is present.76,77 Disease genes that predominantly 
underlie a Leigh-like presentation that may not fit a stringent LS diagnosis also 
include SERAC1 which causes 3-methylglutaconic aciduria with deafness, 
encephalopathy and Leigh-like syndrome (MEGDEL) associated with isolated or 
combined OXPHOS enzyme deficiency.78 These patients often present with atypical 
neuroradiology, or with unusual additional symptoms including abnormal behavior.79  
The emergence of genotype-phenotype relationships 
Historically, strong correlations between a molecular defect and clinical features 
could not be identified among LS patients,2 in part reflecting the low numbers of 
patients for most disease genes. However the increasing utilization of MPS 
technology has facilitated the identification of multiple LS patients with mutations in 
the same gene, enabling the recognition of emerging genotype-phenotype correlations 
(see Table 3 for examples). The presence of these signature features in combination 
with a biochemical deficiency and knowledge of the patient’s ethnicity may suggest a 
specific genetic basis. Beyond having characteristic symptoms, different LS disease 
genes can underlie distinct disease courses, where differences in median age of onset, 
and length of disease course, can be observed (illustrated in Fig 3). For example, 
NDUFS4 mutations appear to be associated with early onset and death, whereas 
patients with mutations in SUCLA2 or the complex IV assembly factor PET100 
experience early onset but a more variable lifespan including survival into 
adolescence.   
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The accumulation of additional patients with an established genetic basis of disease 
and thorough phenotyping may reveal more LS genotype-phenotype correlations. 
More research is required to determine the molecular basis of such relationships, 
although they may be expected to in part reflect tissue-specific effects relating to 
expression levels, function, and or responses to the genetic defect. Being able to 
recognize the genetic or biochemical basis of disease has important utility for guiding 
treatment options, and in some cases can enable life-saving intervention for the 
genetic forms that are most responsive to treatment such as SLC19A3 or BTD 
mutations (outlined in Table 2).   
Established molecular defects indicate a common disorder of energy generation 
Our current understanding of the genetic basis of LS supports impairment in 
mitochondrial energy generation being the key to pathogenesis. However, it appears 
that the specific enzyme or process that is disrupted is not as relevant to molecular 
pathogenesis, given the remarkably diverse range of molecular defects causing LS. 
These include defects of catalytic activity, stability or assembly of individual 
OXPHOS complexes, of mtDNA maintenance and expression, and of PDHc activity 
and cofactors required for enzyme activity (see Table 1, and Supplementary Table, A 
for more detailed information).  
 
The identification of several disease genes that are not known to encode proteins with 
a direct role in OXPHOS or PDHc activity raises new questions about the 
pathogenesis of LS (see Table 1, and Supplementary Table, B for more detailed 
information). Some of these defects appear to cause secondary defects of PDHc or 
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OXPHOS enzymes, which may show variability across patients and tissues.78,80-82 
Such secondary defects have not been reported in patients with biotinidase deficiency 
due to BTD mutations, a treatable condition which can manifest as LS (Table 2),83,84 
although there is evidence of ATP deficiency and complex IV inhibition from animal 
and cellular models.85,86  
 
Mutations in the phospholipid remodeling protein SERAC1 and apoptosis-inducing 
factor AIFM1 may impair OXPHOS by reducing the stability of the mitochondrial 
membrane.78,82 However, the mechanism by which mutations in enzymes involved in 
valine catabolism (ECHS1, HIBCH) and biotin recycling (BTD) impair OXPHOS and 
PDHc activity remains to be determined. These enzymes facilitate pathways that can 
produce substrates for the citric acid cycle,81,87 an important source of electrons for 
OXPHOS. However the relevance of this to pathogenesis is unclear, as is the 
contribution of primary effects of these disorders such as perturbed valine 
catabolism.80,81 Instead, an accumulation of toxic reactive metabolites has been 
suggested to be the mechanism by which ECHS1 and HIBCH mutations impair 
OXPHOS and PDHc activity,81,88 similar to the toxic accumulation of sulfide due to 
ETHE1 mutations described above.43 Although it may not be the primary 
consequence of mutation, an indirect effect on mitochondrial energy generation can 
therefore be sufficient to cause the development of LS.  
 
Our understanding of cerebral energy metabolism further supports the central role of a 
diminished energy supply to the pathogenesis of LS. Brain metabolism accounts for 
~20–25% of resting energy expenditure in adults.89 The metabolic requirements of the 
brain increase during infancy and peak in early childhood, where it uses glucose at a 
17		
rate of up to 66% of the body’s resting metabolism.90 Therefore it is not surprising 
that defects in OXPHOS and energy generation can cause early onset 
neurodegeneration in the form of LS. Studies indicating that the brain’s metabolic 
requirements are highest at ~5 years of age90 are relevant to observations suggesting 
that survival past periods of increased vulnerability in infancy and early childhood 
may predict a life span into and beyond late childhood for patients with LS. This is 
supported by the cohort study of LRPPRC patients, where no metabolic crises were 
observed in patients after the age of 7,37 and suggested by the notably later median 
age at last report relative to the median age of death observed across patients with 
either PET100, NDUFV1 or MTFMT mutations in Figure 3.  
 
The particular vulnerability of the basal ganglia and brain stem structures to 
neurodegeneration in LS patients is unexplained. Positron emission tomography 
studies examining the cerebral metabolic rate for glucose in infants and children 
suggested that the brainstem and basal ganglia/thalamus do not necessarily have the 
highest energy requirement of all examined brain structures in conditions of basal 
metabolism.91 Furthermore the capacity for patients with inherited mitochondrial 
energy generation disorders to develop neuropathological abnormalities distinct from 
LS, including in infancy and early childhood,92 suggests that other factors beyond a 
reduced energy supply must contribute to pathogenesis. Previous studies 
demonstrating differences in mitochondrial protein expression across mouse tissues, 
including between different brain regions,93 imply that cell- and tissue-specific 
responses to a molecular defect of mitochondrial energy generation will also 
contribute to pathogenesis. This is supported by transcriptomic studies of cells and 
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tissues from mitochondrial disease patients demonstrating tissue-specific patterns of 
transcriptional dysregulation.94  
Updating diagnostic strategies to incorporate new knowledge of molecular 
etiologies 
Detailed approaches to diagnosis of Leigh syndrome have been published elsewhere 
18,55. The initial steps remain a detailed medical and family history, physical 
examination including determining extent of multi-organ involvement, measurement 
of laboratory parameters such as lactic acid in blood and CSF, and imaging (MRI and 
magnetic resonance spectroscopy) 18. In patients such as those described in Table 3, 
the phenotype may prompt investigation of a specific gene, such as SURF1 in a child 
with hypertrichosis and relative cognitive sparing 35. However, in most patients the 
next step has traditionally been to measure OXPHOS and PDHc enzyme activities in 
a muscle biopsy and cultured skin fibroblasts respectively, the results of which can 
guide subsequent gene-by-gene analysis. While enzyme testing may often still be 
required for diagnosis, the diagnostic paradigm is increasingly shifting to using MPS 
first, in order to potentially avoid the need for muscle biopsy. Testing gene panels of 
perhaps a few hundred genes is a popular approach, although the rate of discovery of 
novel disease genes means that such panels can become outdated quite quickly. 
Whole exome sequencing can potentially detect mutations in any nuclear gene but 
typically is not a sensitive test for mtDNA mutations, so may need to be accompanied 
by a separate test for mtDNA mutations. Whole genome sequencing can detect 
mutations in nuclear and mtDNA genes, but is less widely available than exome 
sequencing. Each of these approaches has specific advantages and disadvantages 95 96 
but in our experience they can enable molecular diagnosis of LS in more than 60% of 
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patients with a stringent LS diagnosis, as defined by the original criteria of Rahman et 
al2. 
Insights into broader cellular dysfunction: an emerging area for therapeutic 
intervention 
There is a growing body of evidence supporting the contribution of broader cellular 
dysfunction in disorders of mitochondrial energy generation. Recent studies have 
demonstrated that PDHc and OXPHOS defects can induce transcriptional 
dysregulation of multiple cellular pathways including those that regulate RNA and 
protein metabolism.94 These disturbances in cellular metabolism appear to be 
primarily mediated by effects on pathways responsible for sensing and responding to 
nutrient availability, including effects on the expression and activity of regulator of 
cellular growth mTORC1.94 Treatment with rapamycin, an inhibitor of mTORC1, 
improved lifespan and attenuated neurodegeneration in the Ndufs4 knockout mouse 
model of LS,97 supporting the notion that dysregulation of these pathways contributes 
to pathogenesis. More recently, improvement in mitochondrial cristae morphology 
was observed to modestly but significantly improve motor performance, lifespan and 
complex I activity in Ndufs4 knockout mice,98 suggesting that effects on 
mitochondrial morphology may additionally contribute to disease pathology.  
 
Molecular defects of PDHc and OXPHOS may furthermore impair normal cell 
function through mechanisms distinct from energy generation per se. PDHc and 
OXPHOS enzyme defects can produce a cellular environment more conducive for the 
production of reactive oxygen species (ROS). Increased ROS have been observed in 
cellular models of PDHc and OXPHOS enzyme deficiencies,99,100 and there is 
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evidence of increased oxidative damage to proteins in affected brain regions of the 
Ndufs4 knockout mice.101 However these results have been inconsistent,102,103 and 
increases in ROS production do not always correlate with neurodegeneration.104 A 
possible alternative explanation could be that elevated ROS production is simply 
reflecting a highly reduced state of the respiratory chain. This typically leads to a 
partial block in NADH oxidation, with a concomitant decrease in the NAD+/NADH 
ratio.105 This redox imbalance may lead to dysregulation of the signaling pathways 
related to nutrient sensing referred to earlier.94,105 NAD metabolism varies in different 
brain regions106 and could potentially contribute to different susceptibility of 
brainstem and basal ganglia in conditions such as LS. Drugs such as nicotinamide 
riboside that can boost NAD synthesis or PARP inhibitors that can block NAD 
degradation are thus promising agents for treating mitochondrial diseases.107,108 
 
Alleviation of oxidative stress has therefore emerged as a promising avenue of 
therapy for LS and other mitochondrial diseases, including the development of 
antioxidants EPI-743 and RP103, which are currently being examined in clinical 
trials.109 Increased ROS are also implicated in the activation of inflammatory 
pathways which may in turn alter mitochondrial function and produce a state of 
chronic stress that further compromises cellular function.110,111 The contribution of 
oxidative stress to disease pathogenesis may therefore be multifaceted.  
 
Another relevant consequence of the molecular defects observed to cause LS is 
elevation of lactate.2 Increased lactate levels reflect a greater utilization of glycolysis 
for energy generation, and may contribute to lesion development in LS patients, 
including through alterations of pH when lactic acidosis ensues.16 An observed 
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correlation between CSF lactate levels and disease severity in LS patients6 supports 
the pathological significance of lactate. Interestingly, attenuation of lesion 
development and neurological decline in Ndufs4 knockout mice following rapamycin 
treatment was suggested to in part reflect a reduction in toxic glycolytic metabolites 
within the brain.97 Significantly, this study also demonstrated that neurological 
improvement and an increase in lifespan could be achieved independently of an effect 
on the primary defect in complex I assembly. This supports the role of broader 
cellular dysfunction in disease pathogenesis, and the validity of targeting these 
pathways therapeutically. Characterization of the precise molecular mechanisms 
driving disease pathology could therefore have great utility for the development of 
new therapies.  
Conclusion  
Like other mitochondrial diseases, there is currently no effective treatment for LS as a 
group.112 However there are several genetic and biochemical forms of LS that can 
benefit from therapeutic intervention, emphasizing the importance of determining the 
molecular basis of disease in LS patients. Furthermore, confirmation of the genetic 
basis of disease enables access to accurate genetic counseling and assisted 
reproductive technologies. MPS has transformed the approach for determining the 
genetic basis of LS, and therefore has the potential to markedly improve diagnostic 
and clinical outcomes for patients. Consolidating our understanding of the cellular 
mechanisms underlying disease pathology is important for enabling the development 
of novel therapeutics.  
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Figure 1: The development of our understanding of Leigh syndrome. Timeline 
depicting significant advances in the understanding of the biochemical and genetic 
basis of Leigh syndrome. The graph represents the number of new LS disease genes 
identified in each year relative to the timeline. The coloring represents the location of 
the gene, either on the X-chromosome (green), autosome (red), or mitochondrial 
DNA (blue). Abbreviations: CI, CII, CIII, CIV and CV refer to Oxidative 
Phosphorylation Complexes I, II, III, IV and V, respectively; CoQ10, Coenzyme Q10; 
LS, Leigh syndrome; MPS, Massively Parallel Sequencing; PDHc, Pyruvate 
Dehydrogenase Complex. 
 
Figure 2: The biochemical basis of Leigh syndrome.  
Leigh syndrome (LS) is caused by a genetic impairment of the mitochondrial 
pathways of energy generation. Briefly, pyruvate is metabolized by pyruvate 
dehydrogenase (PDHc) to produce acetyl coenzyme A (acetyl CoA), which is utilized 
by the citric acid cycle (TCA) to produce electron donors for the pathway of oxidative 
phosphorylation (OXPHOS). OXPHOS is performed within the mitochondrial inner 
membrane by five multi-protein complexes, known as complexes I to V, and electron 
carriers coenzyme Q (CoQ10) and cytochrome c (Cyt c). Complexes I-IV, often 
referred to as the respiratory chain or electron transfer chain, direct the flow of 
electrons provided by the TCA cycle through the multi-protein complexes. CoQ10 
mediates electron transfer between complex I and complex II to complex III, while 
Cyt c transfers electrons from complex III to complex IV. The respiratory chain 
utilizes the energy produced by this electron transfer to pump protons (H+) through 
complexes I, III and IV into the intermembrane space, generating a proton gradient 
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that can be harnessed by ATP synthase (complex V) to drive the synthesis of ATP. 
Deficiency of PDHc, complexes I-V, and CoQ10, can cause LS.  
 
Figure 3: Genotype-phenotype correlations with respect to disease course. Box 
and whisker plot representation of the ages of onset, death or last report for patients 
with mutations in NDUFS4, NDUFV1 (complex I deficiency), SURF1, PET100 
(complex IV deficiency), SUCLA2 and MTFMT (combined OXPHOS deficiency) as 
reported in the literature. Genotype-phenotype differences in disease course can be 
observed between the genetic and biochemical forms of disease. Data points are 
represented as: error bars depicting minimum and maximum, the box edges depicting 
the 1st and 3rd quartiles, with the line within the box representing the median. Number 
of patients for which information was available: NDUFS4- 21, NDUFV1- 12, SURF1- 
21, PET100- 10, SUCLA2- 31, and MTFMT- 12.  
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Table 1: Genes in which mutations cause Leigh syndrome or Leigh-like syndrome. 
ΔmtDNA = mtDNA deletion.  X-linked inheritance indicated by #, maternal 
inheritance by *, ^indicates sporadic inheritance; all other genes are associated with 
autosomal recessive inheritance. Supplementary Table 1 contains additional 
information on the role of each gene product. 
Biochemical 
deficiency 
Genes 
Pyruvate 
dehydrogenase 
PDHA1#, PDHB, PDHX , DLAT, DLD, LIPT1, LIAS, TPK1, 
SLC19A3, SLC25A19 
Complex I  MTND1*, MTND2*, MTND3*, MTND4*, MTND5*, MTND6*, 
NDUF1V, NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, 
NDUFS7, NDUFS8, NDUFA1#, NDUFA2, NDUFA9, NDUFA10, 
NDUFA12, NDUFAF2, NDUFAF5, NDUFAF6, FOXRED1  
Complex II  SDHA, SDHAF1 
Coenzyme Q10  PDSS2  
Complex III  UQCRQ, BCS1L, TTC19  
Complex IV  MTCO3*, NDUFA4, SURF1, COX10, COX15, SCO2, PET100, 
LRPPRC, TACO1, ETHE1 
Complex V  MTATP6* 
OXPHOS ± PDHc  HIBCH, ECHS1, SERAC1, AIFM1# 
Biotinidase  BTD 
Combined OXPHOS defects - Pathway affected 
Mitochondrial DNA 
maintenance 
FBXL4, POLG, SUCLA2, SUCLG1 
Mitochondrial 
translation  
ΔmtDNA^, MTTI*, MTTK*, MTTL1*, MTTV*, MTTW*, 
MTFMT, GTPBP3, TRMU, EARS2, FARS2, IARS2, NARS2, 
GFM1, GFM2, TSFM, C12orf65, PNPT1 
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Table 2: Available therapeutic options for Leigh syndrome patients, and the genetic and 
biochemical forms that can respond to treatment.  Apart from targeted therapies, all LS patients can 
be offered treatment for symptoms such as acidosis, seizures, dystonia or cardiomyopathy. It is also 
important to ensure good nutrition, aggressive management of intercurrent illnesses and caution with 
anesthesia.113 
Gene or biochemical form Treatment 
Coenzyme Q10 deficiency (PDSS2) Coenzyme Q10 
Ethylmalonic encephalopathy  (ETHE1) Metronidazole and N-acetylcysteine 
Biotin/thiamine-responsive basal ganglia disease (SLC19A3) Thiamine and high dose biotin 
TPK deficiency (TPK1) Thiamine 
Biotinidase deficiency (BTD) Biotin 
Pyruvate dehydrogenase deficiency (PDHA1) Thiamine and high-fat diet 
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Table 3: Characteristic Leigh syndrome disease features, affected ethnicities and founder genotypes associated with the most common nuclear disease genes (all with ≥ 10 patients 
reported). 
Gene and biochemical 
defect 
Characteristic disease features  
 
Ethnicities notably affected Founder / frequent genotypes 
NDUFS4 CI ‘Typical’ LS disease course with death by 3 years Ashkenazi Jews c.462delA with an estimated frequency 
of 1:100025,113  
SURF1 CIV Hypertrichosis, cognitive sparing (Pan-ethnic) c.311_312insATdel10 in Caucasian 
Europeans35 
LRPPRC CIV Mild facial dysmorphism, liver pathology and a course punctuated by episodes of 
acute metabolic decompensation 
Saguenay-Lac-Saint-Jean 
region of Quebec, Canada 
c.1119C>T, p.A354V with an 
estimated carrier frequency of 1:233,37  
SCO2 CIV Hypertrophic cardiomyopathy, spinal muscular atrophy pattern of histopathology 
in skeletal muscle 
(Pan-ethnic) 
 
c.1541G>A, p.E140K39  
PET100 CIV Seizures Lebanese c.3G>C114 
ETHE1 CIV Ethylmalonic aciduria, acrocyanosis, petechiae, gastrointestinal involvement Mediterranean basin and 
Arabian peninsula regions 
c.487C>T, p.R163W38  
SUCLA2 CI, III, IV &V Methylmalonic aciduria, dystonia, deafness, often Leigh-like presentation, Faroese Islanders c.534+1G>A with an estimated carrier 
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 cerebral atrophy, onset in early infancy with long disease duration  frequency of ~1:33 people
4,115  
MTFMT CI, III, IV &V Microcephaly frequently observed 
 
Europeans c.626C>T with an estimated carrier 
frequency of 1:100 in Europeans51 
SERAC1 Multiple Hypoglycemia, liver involvement, behavioral disturbance  (Pan-ethnic) - 
PDHA1 PDHc Lactate:pyruvate ratio <20, agenesis of corpus callosum frequently observed (Pan-ethnic) - 
PDHX 
 
PDHc Lactic acidosis crisis in newborn or in early infancy, cerebral palsy-like 
presentation 
Roma children from Bulgaria  c.1336C>T, p.R446*116  
 
43		
 
Supplementary Table A: Leigh syndrome disease genes that directly affect the 
structure, assembly, stability or activity of the pyruvate dehydrogenase complex 
(PDHc) and OXPHOS enzymes. Pathogenic mutations in these genes have been 
described in patients diagnosed with Leigh or Leigh-like syndrome, or in 
patients with a reported presentation that is compatible with Leigh or Leigh-like 
syndrome. Mitochondrial DNA-encoded genes are denoted with the MT- prefix. 
#with additional deficiency of alpha-ketoglutarate dehydrogenase (α-KGDH) 
and branched chain alpha-ketoacid dehydrogenase (BCKDH) and *additional 
deficiency of the glycine cleavage enzyme system. †PDHc deficiency only 
observed in absence of thiamine pyrophosphate (TPP) in assay medium. AR = 
autosomal recessive. Appropriate references can be obtained from the OMIM 
entry for each gene.  
Biochemical 
deficiency 
Gene Protein function Inheritance 
Pyruvate 
dehydrogenase  
 
 
 
 
 
 
PDHA1 
PDHB  
PDHX  
DLAT 
DLD# 
LIPT1# 
LIAS* 
TPK1† 
SLC19A3† 
SLC25A19† 
Subunit 
Subunit 
Subunit binding protein 
Subunit 
Subunit 
Co-factor attachment 
Co-factor synthesis 
Co-factor synthesis 
Co-factor transporter 
Co-factor transporter 
X-linked 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
Complex I  MTND1   
MTND2  
MTND3  
MTND4  
Subunit 
Subunit 
Subunit 
Subunit 
Maternal 
Maternal 
Maternal 
Maternal 
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MTND5  
MTND6  
NDUFV1 
NDUFV2 
NDUFS1  
NDUFS2  
NDUFS3  
NDUFS4  
NDUFS7  
NDUFS8  
NDUFA1  
NDUFA2  
NDUFA9  
NDUFA10  
NDUFA12  
NDUFAF2  
NDUFAF5  
NDUFAF6  
FOXRED1  
Subunit 
Subunit 
Subunit 
Subunit 
Subunit 
Subunit 
Subunit 
Subunit 
Subunit 
Subunit 
Subunit 
Subunit 
Subunit 
Subunit 
Subunit 
Assembly factor 
Assembly factor 
Assembly factor 
Assembly factor 
Maternal 
Maternal 
AR 
AR 
AR 
AR 
AR 
AR  
AR 
AR 
X-linked 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
Complex II  SDHA  
SDHAF1 
Subunit 
Assembly factor 
AR 
AR 
Coenzyme Q10  PDSS2  CoQ10 synthesis AR 
Complex III  UQCRQ 
BCS1L  
TTC19  
Subunit  
Assembly factor 
Assembly factor 
AR 
AR 
AR 
Complex IV  MTCO3  
NDUFA4  
SURF1  
COX10  
COX15  
Subunit 
Subunit 
Assembly factor 
Assembly factor 
Assembly factor 
Maternal 
AR 
AR 
AR 
AR 
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SCO2  
PET100  
LRPPRC  
TACO1 
ETHE1 
Assembly factor 
Assembly factor 
mRNA stability 
Translational activator 
Sulfide detoxification 
AR 
AR 
AR 
AR 
AR 
Complex V  MTATP6  Subunit Maternal 
Supplementary Table A continued:  
Biochemical deficiency 
Complexes I, III, IV &V 
Pathway 
affected 
Gene  Protein function Inheritance 
Mitochondrial 
DNA 
maintenance 
 
FBXL4  
POLG  
SUCLA2  
SUCLG1  
(Unclear) 
mtDNA replication 
Nucleotide synthesis 
Nucleotide synthesis 
AR 
AR 
AR 
AR 
Mitochondrial 
translation  
mtDNA deletion 
MTTI  
MTTK  
MTTL1  
MTTV  
MTTW  
MTFMT  
GTPBP3 
TRMU 
EARS2 
FARS2  
IARS2 
NARS2 
- 
Mitochondrial tRNA 
Mitochondrial tRNA 
Mitochondrial tRNA 
Mitochondrial tRNA 
Mitochondrial tRNA 
tRNA modification 
tRNA modification 
tRNA modification 
tRNA aminoacylation    
tRNA aminoacylation    
tRNA aminoacylation    
tRNA aminoacylation    
Sporadic 
Maternal 
Maternal 
Maternal 
Maternal 
Maternal 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
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GFM1  
GFM2 
TSFM 
C12orf65  
PNPT1 
Translation elongation 
Ribosome recycling 
Translation elongation 
Mitochondrial peptide release 
Mitochondrial RNA import  
AR 
AR 
AR 
AR 
AR 
Supplementary Table B: LS disease genes that cause secondary impairment of 
mitochondrial energy generation. 
Associated 
biochemical 
deficiency  
Genes Protein function Inheritance 
OXPHOS ± 
PDHc enzyme 
deficiency  
HIBCH  
ECHS1 
SERAC1 
AIFM1 
Valine catabolism 
Valine catabolism 
Phospholipid remodeling 
Assembly factor/apoptosis 
AR 
AR 
AR 
X-linked 
Biotinidase 
deficiency 
BTD Biotin recycling AR 



